Compare PRAX & RGTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRAX | RGTI |
|---|---|---|
| Founded | 2015 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6B | 7.8B |
| IPO Year | 2020 | N/A |
| Metric | PRAX | RGTI |
|---|---|---|
| Price | $304.26 | $15.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 15 | 9 |
| Target Price | ★ $572.13 | $31.89 |
| AVG Volume (30 Days) | 306.4K | ★ 20.0M |
| Earning Date | 05-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $205.64 |
| Revenue Next Year | $6,395.88 | $150.20 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $26.70 | $6.86 |
| 52 Week High | $354.87 | $58.15 |
| Indicator | PRAX | RGTI |
|---|---|---|
| Relative Strength Index (RSI) | 46.59 | 40.61 |
| Support Level | $290.36 | $14.17 |
| Resistance Level | $322.32 | $17.42 |
| Average True Range (ATR) | 16.70 | 1.12 |
| MACD | -3.49 | 0.07 |
| Stochastic Oscillator | 29.77 | 12.17 |
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
Rigetti Computing Inc is engaged in the business of full-stack quantum computing. The company offers full-stack quantum computing platform as a cloud service to a wide range of end-users, directly through its Rigetti QCS platform, and also through cloud service providers. Its proprietary quantum-classical infrastructure provides ultra-low latency integration with public and private clouds for high-performance practical quantum computing. The company has developed the industry's first multi-chip quantum processor for scalable quantum computing systems. Geographically, the company derives the majority of its revenue from the United States.